Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his
thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
